The Journal of Experimental Medicine
Torrey Pines Biolabs
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents
This Article
Right arrow Full Text
Right arrow Full Text (PDF, 590K)
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Arudchandran, R.
Right arrow Articles by Rivera, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Arudchandran, R.
Right arrow Articles by Rivera, J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
© The Rockefeller University Press, 0022-1007/2000/1/47/ $5.00
The Journal of Experimental Medicine, Volume 191, Number 1, January 3, 2000 47-60

Original Article

The Src Homology 2 Domain of Vav Is Required for Its Compartmentation to the Plasma Membrane and Activation of c-Jun NH2-terminal Kinase 1

Ramachandran Arudchandrana, Martin J. Brownb, Matthew J. Peircea, James S. Songa, Juan Zhangc, Reuben P. Siraganianc, Ulrich Blankd, and Juan Riveraa
a Section on Chemical Immunology, National Institute of Arthritis and Musculoskeletal and Skin Diseases, the
b Experimental Immunology Branch, National Cancer Institute,
c Laboratory of Immunology, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Maryland 20892
d Institut Pasteur, Paris 75724, France

Correspondence to: Juan Rivera, Section on Chemical Immunology, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bldg. 10, Rm. 9N228, 10 Center Dr., MSC 1820, Bethesda, MD 20892-1820. Tel:301-496-7592 Fax:301-402-0012 E-mail:juan-rivera{at}nih.gov.

Vav is a hematopoietic cell–specific guanine nucleotide exchange factor (GEF) whose activation is mediated by receptor engagement. The relationship of Vav localization to its function is presently unclear. We found that Vav redistributes to the plasma membrane in response to Fc{isin} receptor I (Fc{isin}RI) engagement. The redistribution of Vav was mediated by its Src homology 2 (SH2) domain and required Syk activity. The Fc{isin}RI and Vav were found to colocalize and were recruited to glycosphingolipid-enriched microdomains (GEMs). The scaffold protein, linker for activation of T cells (LAT), and Rac1 (a target of Vav activity) were constitutively present in GEMs. Expression of an SH2 domain–containing COOH-terminal fragment of Vav inhibited Vav phosphorylation and movement to the GEMs but had no effect on the tyrosine phosphorylation of the adaptor protein, SLP-76 (SH2 domain–containing leukocyte protein of 76 kD), and LAT. However, assembly of the multiprotein complex containing these proteins was inhibited. In addition, Fc{isin}RI-dependent activation of c-Jun NH2-terminal kinase 1 (JNK1) was also inhibited. Thus, Vav localization to the plasma membrane is mediated by its SH2 domain and may serve to regulate downstream effectors like JNK1.

Key Words: Vav, Fc{isin} receptor I, mast cell, glycosphingolipid-enriched microdomains, plasma membrane


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS